Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Fig. 1

Comparison of expression profiles of circulating tumor cells (CTCs) before and after neoadjuvant chemotherapy (NACT). The expression rates of the different transcripts analyzed on CTCs are shown (a) before and (b) after NACT. c The presence of stem cell–like circulating tumor cell (slCTCs) is shown, including aldehyde dehydrogenase 1 (ALDH1)-positive cells and CTCs in epithelial–mesenchymal transition (EMT) before and after NACT. The identification of EMT markers was considered positive if at least one marker (phosphoinositide 3-kinase, AKT2, Twist-related protein 1) was detected in the sample. EpCAM epithelial cell adhesion molecule, ERCC1 excision repair cross-complementing rodent repair deficiency, complementation group 1, HER2 human epidermal growth factor receptor 2, MUC1 mucin 1, cell surface associated

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us